Halper Sadeh Law Firm Targets Four Corporate Transactions
Investors are questioning the fairness of four pending corporate deals as New York-based law firm Halper Sadeh LLC launches investigations into potential fiduciary breaches. The firm is scrutinizing whether recent acquisition and merger terms unfairly favor insiders at the expense of ordinary shareholders across several NASDAQ-listed companies.
The investigations center on four specific transactions: the cash sale of Crinetics Pharmaceuticals to Vertex Pharmaceuticals for $85.00 per share, the merger between Twin Vee PowerCats and USFM Corporation, the NextCure deal with Avere Therapeutics, and the sale of TriCo Bancshares to First Hawaiian. Halper Sadeh alleges that these agreements may include provisions that stifle superior competing offers or provide financial benefits to insiders that are not extended to the broader investor base.
Attorneys Daniel Sadeh and Zachary Halper stated that their firm is evaluating whether these transactions violate federal securities laws. Their objective is to secure increased consideration, additional disclosures, or other equitable relief for affected shareholders. The firm operates on a contingent fee basis for these matters, noting that previous efforts have led to corporate reforms and financial recoveries in cases involving securities fraud and misconduct.
Comments (0)
No comments yet. Be the first!